AustralianSuper rejects better Healthscope Ltd offer

The drama continues with the potential takeover of private hospital operator Healthscope Ltd (ASX: HSO).

AustralianSuper is part of a bidding consortium, along with BGH Capital and a few Canadian pension funds, which put in the initial bid for Healthscope a few weeks ago at $2.36 per share. However, at the time AustralianSuper said it would vote down any other offers – it is already a substantial shareholder. In total the group owns around 14.5% of the shares.

Yesterday, an offer came in for Healthscope at $2.50 from Brookfield, a global real estate manager. This offer is clearly superior to the first for most of Healthscope’s current shareholders.

The problem is that AustralianSuper doesn’t want to sell its shares, it wants to increase its holding of Healthscope. So it wants as low of a price as possible to pay for the new shares it wants to buy.

AustralianSuper is going to reject the Brookfield offer according to the Australian Financial Review.

However, that doesn’t mean the offer will be rejected by Healthscope. The consortium only owns 14.5% of the shares, it’s in the interest of the rest of the shareholders to accept the better offer. Therefore the other shareholders likely have the numbers to accept the Brookfield offer.

Foolish takeaway

I’m not sure who’s going to be the eventual owner of Healthscope, but it appears that both sides aren’t going to offer any more. Brookfield is offering the best deal and AustralianSuper doesn’t want to pay more than its first offer. As I said yesterday in my article, for current shareholders it would probably be best to sell on the market and move on – a price of $2.58 yesterday was more than the best offer price.

I’d want to put my Healthscope money into one of these top shares which are all growing impressively.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.